The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.
about
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Network biology concepts in complex disease comorbiditiesRelationship between renal function and periodontal disease in community-dwelling elderly women with different genotypes.ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic NephropathyNitrolipids in kidney physiology and disease.
P2860
The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@ast
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@en
type
label
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@ast
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@en
prefLabel
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@ast
The PPARγ2 Pro12Ala variant is ...... n people with type 2 diabetes.
@en
P2093
P2860
P50
P1476
The PPARγ2 Pro12Ala variant is ...... in people with type 2 diabetes
@en
P2093
Antonella Monticelli
Emanuela Lapice
Gabriele Riccardi
Sara Cocozza
Sergio Cocozza
P2860
P2888
P356
10.1186/S12967-015-0448-6
P577
2015-03-12T00:00:00Z
P5875
P6179
1049685099